| Imaging of advanced renal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20458484 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To describe current radiological cross-sectional imaging in the detection and staging of advanced renal cell carcinoma (RCC), defined here as RCC reaching beyond the renal capsule, whether by immediate extension or by metastasis. METHODS: Review and summary of current radiological and urological literature, including original articles and reviews, retrieved from the medical data base "PubMed". RESULTS: Multi-detector-row computed tomography (MDCT) shows a sensitivity of up to 100% and specificity of about 90% for retroperitoneal disease, venous tumour thrombus, and metastasis, but limited accuracy for lymphadenopathy in RCC. Magnetic resonance imaging (MRI) is applied as a problem-solving modality, with particular strength in imaging metastasis to brain and bone. However, dynamic, contrast-enhanced- (DCE-) and arterial-spin-labelling (ASL-) MRI may help to monitor early response to angiogenesis inhibitor drugs. Ultrasonography (US) shows limited capability of identifying retroperitoneal disease, venous tumour thrombus extension, and metastasis. Positron Emission Tomography with 18-fluoro-desoxy-glucose (FDG-PET) demonstrates modest accuracy for metastasis of RCC, with positive studies being suspicious, while negative studies cannot reliably exclude disease. CONCLUSIONS: MDCT represents the diagnostic mainstay for the detection and staging of RCC. In the wake of new systemic therapies for advanced RCC, including angiogenesis inhibitor drugs, monitoring treatment response may become a new task for cross-sectional imaging. |
| | |
Authors:
|
Ullrich G Mueller-Lisse; Ulrike L Mueller-Lisse |
Related Documents
:
|
16280234 - Pet/ct in the evaluation of patients with squamous cell cancer of the head and neck. 16619274 - Pet-ct vs contrast-enhanced ct: what is the role for each after chemoradiation for adva... 18555034 - Impact of the introduction of integrated pet-ct into the preoperative staging pathway o... 18024454 - Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose ... 7618564 - Mr imaging of the normal sternoclavicular joint: spectrum of findings. 17451184 - Mri of mouse models of neurological disorders. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-05-11 |
Journal Detail:
|
Title: World journal of urology Volume: 28 ISSN: 1433-8726 ISO Abbreviation: World J Urol Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-21 Completed Date: 2010-08-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307716 Medline TA: World J Urol Country: Germany |
Other Details:
|
Languages: eng Pagination: 253-61 Citation Subset: IM |
Affiliation:
|
Department of Radiology, Institut fuer Klinische Radiologie, Klinikum der Universitaet Muenchen, Ziemssenstrasse 1, 80336, Munich, Germany. ullrich.mueller-lisse@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Renal Cell
/
diagnosis*,
pathology Diagnostic Imaging / methods* Female Fluorodeoxyglucose F18 / diagnostic use Humans Kidney Neoplasms / diagnosis*, pathology Magnetic Resonance Imaging / methods Male Neoplasm Invasiveness / pathology Neoplasm Staging Positron-Emission Tomography / methods Radiographic Image Enhancement Radiopharmaceuticals / diagnostic use Sensitivity and Specificity Tomography, X-Ray Computed / methods Ultrasonography, Doppler |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
Next Document: [Unity in diversity].